Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy

Cancer Treatment Reviews

Volumn 34, Issue 2, 2008, Pages 103-121

  Pantaleo, M A ^a   Nannini, M ^a   Maleddu, A ^a   Fanti, S ^a   Ambrosini, V ^a   Nanni, C ^a   Boschi, S ^a   Biasco, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

11C acetate; 18F FLT; 18FDG; 68Ga DOTANOC; Cancer; EGFr; HER 2; Molecular imaging; PET; Targeted therapies

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ACETIC ACID C 11; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CHOLINE C 11; CHOLINE F 18; CYTOTOXIC AGENT; ERLOTINIB; FLUORINE 18; FLUORO 3 DEOXYTHYMIDINE F 18; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROLEVODOPA F 18; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; METHYLMETHIONINE C 11; NILOTINIB; OCTREOTIDE[1 3 N ACETYLLEUCINE AMIDE TETRAAZACYCLODODECANETETRAACETIC ACID] GA 68; OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE 1,4,7,10 TETRAAZACYCLODECANE N,N',N'',N'' TETRAACETIC ACID] GA 68; PANITUMUMAB; RADIOISOTOPE; SORAFENIB; SUNITINIB; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER RESEARCH; CARCINOID; CLINICAL PRACTICE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; GENOMICS; GLOMUS TUMOR; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MENINGIOMA; METASTASIS; MOLECULAR IMAGING; MOLECULAR THERAPY; NEUROENDOCRINE TUMOR; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PATIENT SELECTION; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROTEOMICS; RECTUM CANCER; REVIEW; THYROID MEDULLARY CARCINOMA;

EID: 40649083557     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.10.001     Document Type: Review

References (228)

1. R.F. Ozols R.S. Herbst Y.L. Colson Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening – a report from the American Society of Clinical Oncology J Clin Oncol 25 2007 146 162
2. C.H. Chung P.S. Bernard C.M. Perou Molecular portrait and the family tree of cancer Nat Gen S32 2002 533 540
3. P. Therasse S. Arbuck E. Eisenhauer New guidelines to evaluate the response to treatment in solid tumours: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
4. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1999 1773 1782
5. K.I. Chung J. Shia N.E. Kemeny Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 2005 1803 1810
6. A.C. Wolff M.E. Hammond N.J. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002; 15;347 :472–480.
8. M. Scartozzi I. Bearzi R. Berardi A. Mandolesi C. Pierantoni S. Cascinu Epidermal growth factor receptor (EGFR) status in primary colorectal tumours does not correlate with EGFR expression in related metastatic sites: implications foe treatment with EGFR-targeted monoclonal antibodies J Clin Oncol 22 2004 4772 4778
9. T. Wakai T. Kanda S. Hirota A. Ohashi Y. Shirai K. Hatakeyama Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumours is associated with a second KIT mutation Br J Cancer 90 2004 2059 2061
10. E. Segal C.B. Sirlin C. Ooi Decoding global gene expression programs in liver cancer by non invasive imaging Nat Biotechnol 25 2007 675 680
11. D.A. Karnofsky Meaningful clinical classification of therapeutic response to anticancer drugs Clin Pharmacol Ther 2 1961 709 712
12. H. Choi C. Charnsangavej S.C. Faria Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753 1759
13. R.S. Benjamin H. Choi H.A. Macapinlac We should desist using RECIST, at least in GIST J Clin Oncol 25 2007 1760 1764
14. A.D. Van Den Abbeele R.D. Badawi Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumours (GISTs) Eur J Cancer 38 Suppl 5 2002 S60 S65
15. G. Antoch J. Kanja S. Bauer Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumours J Clin Med 45 2004 357 365
16. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39 2003 2012 2020
17. 18FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumours J Nucl Med 45 2004 17 21
18. G.W. Goerres R. Stupp G. Barghouth The value of PET, CT, and in line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate Eur J Nucl Med Mol Imag 32 2005 153 162
19. Van den Abbeele, Melenewsky Y, de Vries D, et al. Imaging kinase target inhibition with SU11248 by FDG PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumours (I-R-GIST). Proc Am Soc Clin Oncol 2005; [abstract 9006].
20. E. Goshen T. Davidson S.T. Zwas D. Aderka PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan Technol Cancer Res Treat 5 2006 37 43
21. C.G. Willet D.G. Duda E. Di Tomaso Complete pathological response to bevacizumab and chemoradiotherapy in advanced rectal cancer Nat Clin Pract Oncol 4 2007 316 321
22. K. Kawada K. Murakami T. Sato Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors Jpn J Clin Oncol 37 2007 44 48
23. H. Su C. Bodenstein R. Dumont Monitoring glucose utilization by positron emission tomography for prediction of treatment response to epidermal growth factor receptor kinase inhibitors Clin Cancer Res 12 2006 5659 5667
24. D.S. Dorow C. Cullicane N. Conus Multitracer small-animal PET imaging of the tumor response to the novel pan-Erb-B inhibitor Eur J Nucl Med Mol Imag 33 2006 441 452
25. R.J. Motzer M.D. Michaelson B.G. Redman Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 16 24
26. M.J. Ratain T. Eisen W.M. Stadler Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 2505 2512
27. Llovet JM, Ricci S, Mazzaferro P, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2007. [abstract LBA1].
28. W.A. Weber H. Wieder Monitoring chemotherapy and radiotherapy of solid tumours Eur J Nucl Med Mol Imag 33 2006 27 37
29. M.E. Juweid B.D. Cheson Positron emission tomography and assessment of cancer therapy New Engl J Med 354 2006 496 507
30. 18F-FDG PET as a indicator of therapeutical response in patients in National Cancer Institute trials J Nucl Med 47 2006 1059 1066
31. R.L. Whal K. Zasadny M. Helvie G.D. Hutchins B. Weber R. Cody Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Oncol 11 1993 2101 2111
32. 18F-fluorodoxy- d -glucose to predict the pathological response of breast cancer to primary chemotherapy J Clin Oncol 18 2000 1676 1688
33. 18F-FDG PET i san early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer J Nucl Med 47 2006 1241 1248
34. F. Lordick K. Ott Bj Krause PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet Oncology 8 2007 797 807
35. K. Ott U. Fink K. Becker Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial J Clin Oncol 21 2003 4604 4610
36. 18F-fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 2000 1689 1695
37. 18F-FDG PET J Nucl Med 46 2005 1144 1150
38. N. Avril S. Sassen B. Schntaleldt Prediction of response to neoadjuvant chemotherapy by sequential F-18fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer J Clin Oncol 23 2005 7445 7453
39. H.A. Wieder B.L. Brucher F. Zimmermann Time course of tumour metabolic activity during chemoradiotherapy of eosophageal squamous cell carcinoma and response to treatment J Clin Oncol 22 2004 900 908
40. W.A. Weber K. Ott K. Becker Prediction to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 2001 3058 3065
41. W.A. Weber V. Petersen B. Schmidt Positron emission tomography in non small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use J Clin Oncol 21 2003 2651 2657
42. 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery J Nucl Med 47 2006 14 22
43. C.P. Duong R.J. Hicks L. Weih FDG PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer Eur J Nucl Med Mol Imag 33 2006 770 778
44. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer Eur J Nucl Med Mol Imag 34 2007 463 471
45. 18F]-2-fluoro-2-deoxy- d -glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer J Clin Oncol 23 2005 8362 8370
46. W.A. Weber R. Figling Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med 48 2007 36S 44S
47. 18F-fluorodeoxy- d -glucose-poistron emission tomography/computed tomography in non small cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy Clin Cancer Res 12 2006 97 106
48. C. Capirci L. Rampin P.A. Erba Sequential FDG PET/CT reliably predicts response of locally advanced rectal cancer to neoadjuvant chemo-radiation therapy Eur J Ncl Med Mol Imag 34 2007 1576 1582
49. R.S. Andrade D.E. Heron B. Degirmenci Post-treatment assessment of response using FDG PET/CT for patients treated with definitive radiation therapy for head neck cancers Int J Rad Oncol Biol Phys 65 2006 1315 1322
50. R.J. Cerfolio A.S. Bryant B. Ohja A.A. Bartolucci M.A. Eloubeidi The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy J Thorac Cardiovasc Surg 129 2005 1232 1241
51. M. Mamede P. Abreu-E-Lima M.R. Oliva V. Nose H. Mamon V.H. Gerbaudo FDG PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results Am J Clin Oncol 30 2007 377 388
52. 18F-FDG PET/CT J Nucl Med 48 2007 744 751
53. H. Shinotoh D.B. Calne The use of PET in Parkinson’s disease Brain Cogn 28 1995 297 310
54. 18F-DOPA PET for detection of gastrointestinal carcinoid tumours Radiology 220 2001 373 380
55. A. Becherer M. Szabò G. Karanikas Imaging of advanced neuroendocrine tumours with (18)F-FDOPA PET J Nucl Med 45 2004 1161 1167
56. K. Pacak G. Eisenhofer J.A. Carrasquillo C.C. Chen S.T. Li D.S. Goldstein 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma Hypertension 38 2001 6 8
57. 18F-DOPA whole-body PET – initial results Radiology 222 2002 507 512
58. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels Eur J Nucl Med 28 2001 64 71
59. L. Gourgiotis N.J. Sarlis J.C. Reynolds C. VanWaes M.J. Merino K. Pacak Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography J Clin Endocrinol Metab 88 2003 637 641
60. 18F-DOPA positron emission tomography for the detection of glomus tumours Eur J Nucl Mol Imag 30 2003 689 694
61. 18F]FDG in the imaging of small cell lung carcinoma: preliminary results Eur J Nucl Med Mol Imag 30 2003 1266 1269
62. A. Dimitrakopoulou-Strauss L.G. Strauss C. Burger Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro- l -dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis J Nucl Med 42 2001 248 256
63. 111In-pentetreotide negative GEP tumours Nucl Med Commun 28 2007 473 477
64. 18F-DOPA PET: a prospective, diagnostic accuracy study Lancet Oncol 7 2006 728 734
65. H. Konno T. Arai T. Tanaka Antitumour effect of a neutralizing antibody to vascular endothelial growth factor on liver metastases of endocrine neoplasm Jpn J Cancer Res 89 1998 933 939
66. M. Kulke H.J. Lenz N.J. Meropol A phase two study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumours (NETs) J Clin Oncol 23 2005 310s [suppl; abstr 4008]
67. J.C. Yao C. Ng P.M. Hoff Improved progression free survival (PFS), and rapid, sustained decrease in tumour perfusion among patients with advanced carcinoid treated with bevacizumab J Clin Oncol 23 2005 16s [ASCO annual meeting proceedings]
68. J.C. Reubi J.C. Schär B. Waser Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of human somatostatin radiotracers selected for scintigraphy and radiotherapeutic use Eur J Nucl Med 27 2000 273 282
69. A. Heppeler S. Froidevaux A.N. Eberle H.R. Maecke Receptor targeting for tumour localisation and therapy with radiopeptides Curr Med Chem 7 2000 971 994
70. 68Ga DOTATOC PET Eur J Nucl Med Imag 31 2004 466
71. 68Ga]-DOTA-D Phe1-Tyr3-octreotide (DOTATOC): first results in meningioma patients J Nucl Med 42 2001 1053 1056
72. M. Hofmann H. Maecke A.R. Börner Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data Eur J Nucl Med 28 2001 1751 1757
73. 90Y-DOTATOC therapy Eur J Nucl Med Mol Imag 33 2006 1115 1122
74. S. Adams R. Baum T. Rink P.M. Schumm-Dräger K.H. Usadel G. Hör Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours Eur J Nucl Med 25 1998 79 83
75. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours Eur J Med Mol Imag 23 2007 [epub ahead of pint]
76. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors Mol Imaging Biol 5 2003 42 48
77. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumours: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 2007 508 518
78. D. Wild J.S. Schmitt M. Ginj DOTA-NOC, high affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur J Nucl Med Mol Imag 30 2003 1338 1347
79. 68Ga DOTATOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 Eur J Nucl Med Mol Imag 2004
80. 18F-DOPA PET/CT: preliminary report of seven MEN1 cases J Nucl Med 48 S2 2007 383
81. W. Negendank Studies of human tumours by MRS: a review NMR Biomed 5 1992 303 324
82. A. Ramirez De Molina A. Rodriguez-Gonzales R. Gutierrez Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate and human colorectal cancers Biochem Biophys Res Commun 296 2002 580 583
83. 11C]choline J Nucl Med 38 1997 842 847
84. 11C]choline J Nucl Med 38 suppl 1997 [abstract 250P]
85. T. Hara N. Kosaka H. Kishi PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 1998 990 995
86. 11C-choline PET J Nucl Med 41 2000 1507 1513
87. 18F-FDG PET Ann Nucl Med 18 2004 409 417
88. T. Torizuka T. Kanno M. Futatsubashi Imaging of gynaecologic tumours: comparison of (11)C-choline PET with (18)F-FDG PET J Nucl Med 44 2003 1051 1056
89. T. Yanagawa H. Watanabe T. Inoue Carbon-11 choline positron emission tomography in musculoskeletal tumours: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography J Comput Assist Tomogr 27 2003 175 182
90. 18F]fluoro-2-deoxy- d -glucose (FDG) PET Ann Nucl Med 18 2004 29 34
91. J.N. Talbot F. Gutman L. Fartoux PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F] FDG PET/CT Eur J Nucl Med Mol Imag 33 2006 1285 1289
92. 18F-choline PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imag 33 2006 1387 1398
93. F. Fazio M. Picchio C. Messa Is choline the most appropriate tracer for prostate cancer? For Eur J Nucl Med Mol Imag 31 2004 753 756
94. K. Zöphel J. Kotzerke Is choline the most appropriate tracer for prostate cancer? Against Eur J Nucl Med Mol Imag 31 2004 756 759
95. 18F]fluoro- d -glucose in tumour imaging with positron emission tomography Mol Imaging Biol 4 2002 267 273
96. 11C-choline PET/CT J Nucl Med 47 2006 1249 1254
97. 11C-choline positron emission tomography Eur Urol 42 2002 18 23
98. 11C-choline PET and PET/CT in patients with suspected prostate cancer Eur J Nucl Med Mol Imag 34 2007 45 53
99. 11C]choline uptake in prostate cancer: a PET study Eur J Nucl Med Mol Imag 31 2003 317 324
100. 11C-choline PET/CT with histopathologic step-section analysis J Nucl Med 46 2005 1642 1649
101. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging Urol Int 74 2005 214 220
102. 11C]choline does not correlate with cell proliferation in human prostate cancer Eur J Nucl Med Mol Imag 32 2005 668 673
103. C. Nanni P. Castellucci M. Farsad D. Rubello S. Fanti (11)C/(18)F-choline or (11)C/(18)F-acetate PET in prostate cancer: may a choice be recommended? Eur J Nucl Med Mol Imag 34 2007 1704 1705
104. 11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer Eur J Nucl Med Mol Imag 29 2002 1492 1495
105. J. Kotzerke B.G. Volkmer B. Neumaier J.E. Gschwend R.E. Hautmann S.N. Reske Carbon-11-acetate positron emission tomography can detect local recurrence of prostate cancer Eur J Nucl Med Mol Imag 29 2002 1380 1384
106. 11C acetate PET imaging of prostate cancer Eur J Med 43 2002 181 186
107. 11C acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse J Nucl Med 44 2003 549 555
108. 11C]choline PET for detection of metastases of prostate cancer Nuklearmedizin 42 2003 25 30
109. 18F] fluorodeoxyglucose-positron emission tomography J Urol 169 2003 1337 1340
110. J. Kotzerke J. Prang B. Neumaier Experience with carbon-11-choline positron emission tomography in prostate carcinoma Eur J Nucl Med 27 2000 1415 1419
111. 18F]FDG with positron emission tomography in recurrence of prostate cancer AJR Am J Roentgenol 179 2002 482 484
112. 18F–fluoride in bone imaging with emphasis on prostate and breast Sem Nucl Med 36 2006 73 92
113. R.E. Coleman T.R. DeGrado S. Wang Preliminary evaluation of F-18-fluocholine (FCH) as a PET tumour imaging agent. Scientific papers Clin Pos Imag 3 2000 147
114. A. Liu K.E. Carlson J.A. Katzenellenbogen Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography J Med Chem 35 1992 2113 2129
115. 18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution J Med Chem 38 1995 816 825
116. T.A. Bonasera J.P. O’Neil M. Xu Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons J Nucl Med 37 1996 1009 1015
117. 18F-FDG in patients with progressive, metastatic prostate cancer J Nucl Med 45 2004 366 373
118. F. Dehdashti J. Picus J.M. Michalski Positron tomographic assessment of androgen receptors in prostatic carcinoma Eur J Nucl Med Mol Imag 32 2005 344 350
119. J.S. Rasey J.R. Grierson L.W. Wiens P.D. Kolb J.L. Scwartz Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells J Nucl Med 43 2002 1210 1217
120. A.F. Shields J.R. Grierson B.M. Dohmen Imaging proliferation in vivo with F-18-FLT and positron emission tomoghraphy Nat Med 1998 1334 1336
121. A.K. Buck H. Schirrmeister M. Hetzel 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules Cancer Res 62 2002 3331 3334
122. 18FLT PET for diagnosis and staging of thoracic tumours Eur J Nucl Med Mol Imag 30 2003 1407 1412
123. 18F]-fluoro-2-deoxy- d -glucose in positron emission tomography for colorectal cancer Eur J Nucl Med Mol Imag 30 2003 988 994
124. 18F-3-fluoro-3-deoxy- l -thymidine: a new tracer or staging of metastatic melanoma? J Nucl Med 44 2003 1927 1932
125. 18F-3-fluoro-3-deoxy- l -thymidine Clin Cancer Res 10 2004 1685 1690
126. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study Eur J Nucl Med Mol Imag 31 2004 720 724
127. 18F-FLT) – a pilot study EJSO 32 2006 39 43
128. 11C-Methylmetionine as markers of increased transport and proliferation in brain tumours J Nucl Med 46 2005 1948 1958
129. Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of (18)FLT and (18)FDG uptake on PET with Ki-67 immunohistochemistry in non small lung cancer. Eur J Nucl Med Mol Imag 2007. [epub ahead of print].
130. 18F-fluorodeoxyglucose-positron emission tomography Chest 129 2006 393 401
131. 18F-FGD PET in oesophageal cancer J Nucl Med 46 2005 400 404
132. 18FDG PET J Nulc Med 45 2004 226 231
133. H. Vesselle J. Grierson M. Muzi In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumours Clin Cancer Res 8 2002 3315 3323
134. 18F-FGD J Nucl Med 2005 945 952
135. 18FDG J Nucl Med 44 2003 1426 1431
136. D.L. Francis A. Freeman D. Visvikis In vivo imaging of cellular proliferation in colorectal using positron emission tomography Gut 52 2003 1602 1606
137. 18FLT PET Eur J Nucl Med Mol Imag 31 2004 928
138. B.S. Pio C.K. Park R. Pietras Usefulness of 3-[F-18]-fluoro-3-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy Mol Imaging Biol 8 2006 36 42
139. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imag 2007. [epub ahead of print].
140. H.A. Wieder H. Geinitz R. Rosenberg PET imaging with 3-[F-18]-fluoro-3-deoxythymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer Eur J Nucl Med Mol Imag 34 2007 878 883
141. 18F-fluorothymidine as a new marker for monitoring tumour response to antiproliferative therapy in vivo with positron emission tomography Cancer Res 63 2003 3791 3798
142. 18F-fluorothymidine for monitoring of tumour response to radiotherapy and photodynamic therapy in mice J Nucl Med 45 2004 1754 1758
143. 18F-fluorothymidine microPET studies in tumor xenograft in mice J Nucl Med 2005 1851 1857
144. J. Leyton J.R. Latigo M. Perumal H. Dhaliwal Q. He E.O. Aboagye Early detection of tumour response to chemotherapy by 3-Deoxy-3-[18)F]-fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumour model in vivo Cancer Res 15 2005 4202 4210
145. S. Apisarnthanarax M.M. Alauddin F. Mourtada Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumour models Clin Cancer Res 12 2006 4590 4597
146. H. Barthel P. Price E.O. Aboagye Small-animal imaging of tumour proliferation with PET Lancet Oncol 5 2004 100
147. 18F-fluorothymidine PET J Nucl Med 46 2005 114 120
148. Atkinson D, Mladek A, Carlson B, et al. EGFR inhibition results in suppression of thymidine kinase-1 activity and a corresponding decrease in FLT uptake in A431 cells and xenografts. [abstract 288].
149. M. Yoshimoto A. Waki Y. Yonekura Characterisation of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells Nucl Med Biol 28 2001 117 122
150. P. Shreve P.C. Chiao H.D. Humes M. Schwaiger M.D. Gross Carbon-11-acetate PET imaging in renal disease J Nucl Med 36 1995 1595 1601
151. J. Kotzerke C. Linné M. Meinhardt [1-(11)C] Acetate uptake is not increased in renal cell carcinoma Eur J Nucl Med Mol Imag 34 2007 884 888
152. 11C-acetate and 18F-FDG in prostate cancer patients Eur J Nucl Med Mol Imag 30 2003 607 611
153. G. Sandblom J. Sorensen N. Lundin Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy Urology 67 2006 996 1000
154. 11C-acetate clearance in nasopharyngeal carcinoma Nucl Med Commun 20 1999 131 134
155. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses J Nucl Med 44 2003 213 221
156. D. Mathews O.K. Oz Positron emission tomography in prostate and renal cell carcinoma Curr Opin Urol 12 2002 381 385
157. 11C-acetate: a new tracer for the evaluation of hepatocellular carcinoma J Nucl Med. 44 2003 222 223
158. C.L. Ho S. Chen D.W. Yeung T.K. Cheng Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma J Nucl Med 48 2007 902 909
159. C. Schiepers J. Nuyts G. Bormans Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET J Nucl Med 38 1997 1970 1976
160. R.A. Hawkins Y. Chio S.C. Huang Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET J Nucl Med 33 1992 633 642
161. 18F–fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology 209 1998 253 258
162. H. Schirrmeister A. Guhlmann J. Kotzerke Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography J Clin Oncol 17 1999 2381 2389
163. 18F-labeled NaF PET in newly diagnosed lung cancer J Nucl Med 42 2001 1800 1804
164. M. Hetzel C. Arslandemir H.H. Konig F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness and impact on patient management J Bone Min Res 18 2003 2206 2214
165. 18F–fluoride PET/CT J Nucl Med 45 2004 272 278
166. 18F–fluoride PET/CT J Nucl Med 47 2006 287 297
167. P.L. Jager W. Vaalburg J. Pruim E.G. de Vries K.J. Langen D.A. Piers Radiolabeled amino acids: basic aspects and clinical applications in oncology J Nucl Med 42 2001 432 445
168. 11C-methionine for diagnosis of recurrent brain tumour and radiation injury Acta Radiol 32 1991 197 202
169. B. Kaschten A. Stevenaert B. Sadzot Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine J Nucl Med 39 1998 778 785
170. 18FDG PET Eur J Nucl Mol Imag 29 2002 176 182
171. 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value Eur J Med Mol Imag 32 2005 39 51
172. 18F-FDG PET Eur J Nucl Med Mol Imag 32 2005 52 59
173. O. De Witte I. Goldberg D. Wikler Positron emission tomography with injection of methionine as a prognostic factor in glioma J Neurosurg 95 2001 746 750
174. 18F Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neuroncol 2007. [epub ahead of print].
175. 11C-methionine for PET-guided stereotactic brain biopsy of gliomas J Nucl Med 45 2004 1293 1298
176. 11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence AJNR 27 2006 1432 1437
177. D. Ribom H. Engler E. Blomquist A. Smits Potential significance of (11)C-methionine PET as marker for the radiosensitivity of low-grade gliomas Eur J Nucl Med Mol Imag 29 2002 632 640
178. J. Nuutinen P. Sonninen P. Lehikoinen Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma Int J Rad Oncol Biol Phys 48 2000 43 52
179. M. Wurker K. Herholz J. Voges Glucose consumption and methionine uptake in low grade gliomas after iodine-125 brachytherapy Eur J Nucl Med 23 1996 583 586
180. 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds Stereotact Funct Neurosurg 69 1997 129 135
181. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy Int J Rad Oncol 66 2006 339 344
182. 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas Eur J Nucl Med Mol Imag 33 2006 516 524
183. B.N. Tang N. Sadeghi F. Branle O. De Witte D. Wilker S. Goldman Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma J Neuro-Oncol 71 2005 161 168
184. K. Herholz L.W. Kracht W.D. Heiss Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET J Neuroimag 13 2003 268 271
185. J.N. Rich D.A. Reardon T. Peery Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 2004 133 142
186. D.A. Haas-Kogan M.D. Prados T. Tihan Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib J Natl Cancer Inst 97 2005 880 887
187. G. Dresemann Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series Ann Oncol 16 2005 1702 1708
188. X. Geets J.F. Daisne V. Gregoire Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG PET and CT Radiother Oncol 71 2004 267 273
189. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer J Nucl med 43 2002 46 55
190. 11C-methionine positron emission tomography J Urol 173 2005 66 69
191. J. Baselga The EGFR as a target for anticancer therapy – focus on cetuximab Eur J Cancer 37 2001 S16 S22
192. D.S. Salomon R. Brandt F. Ciardiello N. Normanno Epidermal growth factor-related peptides and their receptor in human malignancies Critical Rev Oncol Hematol 19 1995 183 232
193. N.S. Goldstein M. Armin Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system Cancer 92 2001 1331 1346
194. D. Vallbohmer W. Zhang M. Gordon Molecular determinants of Cetuximab efficacy J Clin Oncol 23 2005 3536 3544
195. H.J. Lenz E. Van Cutsem S. Khambata-Ford Multicenter phase II trial and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines J Clin Oncol 24 2006 4914 4921
196. A.P. Dei Tos I. Ellis Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer 41 2005 1383 1392
197. J.G. Paez P.A. Janne J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
198. T.J. Lynch D.W. Bell R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New Engl J Med 350 2004 2129 2139
199. W. Cai K. Chen L. He Quantitative PET of EGFR expression in xenograft-bearing mice using (64)Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody Eur J Nucl Med Mol Imag 34 2007 850 858
200. Pantaleo MA, Fanti S, Lollini PG, Boschi S, Biasco G. PET detection of Epidermal Growth Factor receptor in colorectal cancer: a real predictor to cetuximab treatment? Eur J Nucl Med Imag 2007. [epub ahead of print].
201. G. Piazzi P. Paterini C. Ceccarelli M.A. Pantaleo G. Biasco Molecular determination of epidermal growth factor receptor in normal and neoplastic colrectal mucosa Br J Cancer 95 2006 1525 1528
202. T. Bonasera G. Ortu Y. Rozen Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase Nucl Med Biol 28 2001 359 374
203. E. Mishani G. Abourbeh O. Jacobson High-affinity epidermal growth factor receptor (EGFr) irreversibile inhibitors with diminuished chemical reactivities as positron emission tomography (PET)-imaging agents candidates of EGFr overexpressing tumors J Med Chem 48 2005 5337 5348
204. 124I-labeled small molecular tracer and positron emission tomography Mol Imaging Biol 8 2006 262 277
205. D.J. Slamon B. Leyland-Jones S. Shack Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 New Engl J Med 344 2001 783 792
206. P.M. Smith-Jones D.B. Solit T. Akhurst F. Afroze N. Rosen S.M. Larson Imaging the pharmacodynamics of HER-2 degradation in response to Hsp90 inhibitors Nat Biotechnol 22 2004 701 706
207. 18F-FDG PET J Nucl Med 47 2006 793 796
208. M.K. Robinson M. Doss C. Shaller Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody Cancer Res 65 2005 1471 1478
209. M.C. Heinrich C.L. Corless G.D. Demetri Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 Dec 1 2003 4342 4349
210. E. Tamborini L. Bonadiman A. Greco A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 1 2004 294 299
211. G.D. Demetri A.T. van Oosterom C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 2006 1329 1338
212. K.E. Kil Y.S. Ding K.S. Lin Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec) Nucl Med Biol 34 2007 153 163
213. D.W. Leung G. Cachianes W.J. Kuang D.V. Goeddel N. Ferrara Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1989 1306 1309
214. N. Ferrara H.P. Gerber J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
215. H. Hurwitz L. Fehrenbacher W. Novotny Bevacizumab plus irinotecan, fluouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
216. B.J. Giantonio P.J. Catalano N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544
217. W. Cai X. Chen Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression Front Biosci 12 2007 4267 4279
218. D.R. Collingridge V.A. Carroll M. Glaser The development of [(124)]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography Cancer Res 62 2002 5912 5919
219. G.C. Jayson J. Zweit A. Jackson Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of anti-angiogenic antibodies J Natl Cancer Inst 94 2002 1484 1493
220. W. Cai K. Chen K.A. Mohamedali PET of vascular endothelial growth factor receptor expression J Nucl Med 47 2006 2048 2056
221. I. Verma N. Somia Gene therapy-promises, problems and prospects Nature 389 1997 239 242
222. I. Penuelas U. Haberkorn S. Yaghoubi S.S. Gambhir Gene therapy imaging in patients for oncological applications Eur J Nucl Med Mol Imag 32 2005 S384 S403
223. 18F]-FHBG): a new potential imaging agent for viral infection and gene theapy using PET Nucl Med Biol 25 1998 175 180
224. S.S. Gambhir J.R. Barrio L. Wu Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabelled ganciclovir J Nucl Med 39 1998 2003 2011
225. 18F]-FHBG Nat Protocol 1 2006 3069 3075
226. I. Puenelas G. Mazzolini J.F. Boán Positron emission tomography imaging of adenoviral mediated transgene expression in liver cancer patients Gastroenterology 128 2005 1787 1795
227. A. Jacobs J. Voges R. Reszka Positron-emission tomography of vector mediated gene expression in gene therapy for gliomas Lancet 358 2001 727 729
228. S.S. Yaghoubi J.R. Barrio M. Namavari Imaging progress of herpes simplex virus type 1 thymidie kinase suicide gene therapy in living subjects with positron emission tomography Cancer Gene Ther 12 2005 329 339